Abstract
Histopathology provides the basis for breast patient management and prognosis and requires careful examination of well-processed material by trained pathologists. They will assess the material provided to them, either cytology samples, biopsy specimens or surgical excision material, and will provide not only diagnosis, but a large quantity of clinically important information for each case. Whilst there is a wide range of potential breast lesion diagnoses, this chapter will address those entities regarded as ‘high-risk’, pre-invasive (precursors) of invasive breast cancer and also diagnosis and prognostic and predictive factors for invasive breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Reference
Lips EH, Kumar T, Megalios A, Visser LL, Sheinman M, Fortunato A, et al. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Nat Genet. 2022;54(6):850–60.
Suggested Reading
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–66.
Andersson Y, Bergkvist L, Frisell J, de Boniface J. Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. Breast Cancer Res Treat. 2018 Sep;171(2):359–69.
Blamey RW, Pinder SE, Ball GR, Ellis IO, Elston CW, Mitchell MJ, et al. Reading the prognosis of the individual with breast cancer. Eur J Cancer. 2007 Jul;43(10):1545–7.
van Dooijeweert C, van Diest PJ, Ellis IO. Grading of invasive breast carcinoma: the way forward. Virchows Arch. 2022;480(1):33–43. https://doi.org/10.1007/s00428-021-03141-2. Epub 2021 Jul 1. PMID: 34196797; PMCID: PMC8983621
Dyrstad SW, Yan Y, Fowler AM, Colditz GA. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res Treat. 2015 Feb;149(3):569–75.
Foschini MP, Miglio R, Fiore R, Baldovini C, Castellano I, Callagy G, et al. Pre-operative management of pleomorphic and florid lobular carcinoma in situ of the breast: report of a large multi-institutional series and review of the literature. Eur J Surg Oncol. 2019;45(12):2279–86.
Fox SB, Webster F, Chen CJ, Chua B, Collins L, Foschini MP, et al. Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: recommendations from the international collaboration on cancer reporting (ICCR). Histopathology. 2022;81:467–76. https://doi.org/10.1111/his.14725. Epub ahead of print.
Wen HY, Brogi E. Lobular Carcinoma In Situ. Surg Pathol Clin. 2018;11(1):123–45.
Zhang H, Karakas C, Tyburski H, Turner BM, Peng Y, Wang X, et al. HER2-low breast cancers: current insights and future directions. Semin DiagnPathol 2022 :S0740-2570(22)00057–0.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Pinder, S.E., Ng, W. (2023). Pathology of High-Risk Breast Lesions, Pre-Invasive and Invasive Breast Cancer. In: Markopoulos, C., Karakatsanis, A. (eds) Breast Cancer Management for Surgeons. Springer, Cham. https://doi.org/10.1007/978-3-031-37752-5_4
Download citation
DOI: https://doi.org/10.1007/978-3-031-37752-5_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-37751-8
Online ISBN: 978-3-031-37752-5
eBook Packages: MedicineMedicine (R0)